ERBB2 and breast carcinoma: In order to identify sporadic breast cancers sensitive to DSB-inducing agents, many studies have focused on triple-negative (hormone receptor-negative and HER2-negative) breast cancers (TNBCs), as these cluster with BRCA1-mutated breast cancers within the basal-like molecular subtype [13,14].